Brief: Sino Biopharmaceutical Says Category 1 Innovative Drug Benmelstobart Injection "Benmelstobart (Tqb2450)" Obtained Approval For Marketing From NMPA
09/05/2024 07:09
May 9 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* CATEGORY 1 INNOVATIVE DRUG BENMELSTOBART INJECTION
"BENMELSTOBART (TQB2450)" OBTAINED APPROVAL FOR MARKETING FROM
NMPA
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up